Establishing A Preclinical Multidisciplinary Board for Brain Tumors.

CONCLUSIONS:  We report a comprehensive preclinical trial platform to assess the therapeutic activity of conventional and novel treatments among rare brain tumor subtypes. It also enables the development of complex, combination treatment regimens that should deliver optimal trial designs for clinical testing.  Post-irradiation gemcitabine infusion should be tested as new treatments of SEP and CPC.
PMID: 29301833 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - January 4, 2018 Category: Cancer & Oncology Authors: Nimmervoll B, Boulos N, Bianski BM, Dapper J, DeCuypere M, Shelat AA, Terranova S, Terhune HE, Gajjar A, Patel YT, Freeman BB, Onar-Thomas A, Stewart CF, Roussel MF, Guy RK, Merchant TE, Calabrese C, Wright KD, Gilbertson RJ Tags: Clin Cancer Res Source Type: research